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Abstract 
Concurrence of nonalcoholic steatohepatitis (NASH) with autoimmune hepatitis (AIH) 
is a rare condition that is challenging to diagnosis, due to the relatively high prevalence 
of autoantibodies in NASH. It is also difficult to determine the most effective treatment 
as corticosteroids are likely to worsen NASH despite being effective in the treatment of 
AIH. In this case report, we present a female diagnosed with NASH-AIH overlap with 
accompanying diabetes mellitus, who successfully achieved normalization of serum 
alanine aminotransferase levels following prednisolone therapy and weight loss. A 
follow-up liver biopsy performed 40 months after the initial diagnosis showed only 
minimal inflammatory infiltrates in the portal area without any NASH histology. 
Resolution of NASH, in conjunction with a reduction in hepatic fibrosis, might suggest 
that prednisolone itself does not aggravate steatohepatitis, but rather prevents disease 
progression. Appropriate immunosuppressive treatment may therefore be an important 
component of the optimum therapy for NASH-AIH overlap. Case Rep Gastroenterol 2011;5:553–557 
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Introduction 
Concurrence of more than one disease in the liver (thereafter ‘overlap’) may have a 
significant impact on disease progression. Due to a progressive increase in the prevalence 
of nonalcoholic fatty liver disease (NAFLD) associated with ‘endemic’ obesity, overlapped 
NAFLD, especially in its necroinflammatory form of nonalcoholic steatohepatitis 
(NASH), has gained clinical relevance in the diagnosis and prognosis of chronic liver 
disease. In fact, patients with chronic hepatitis C and NASH have more advanced stages 
of fibrosis accompanied by more severe metabolic syndrome than those with chronic 
hepatitis C or chronic hepatitis C and nonalcoholic steatosis [1]. Regarding overlap with 
other forms of chronic liver disease, NASH-autoimmune hepatitis (AIH) overlap 
syndrome has received special attention for several reasons. First, histological diagnosis of 
NASH-AIH overlap is absolutely required, owing to previous reports that autoantibodies 
were present in about one quarter of patients with NAFLD [2] and that without liver 
biopsy [3], almost all the female patients were incorrectly diagnosed with AIH. Second, 
the optimum treatment regimen to achieve biochemical remission has been difficult to 
standardize; corticosteroids are likely to worsen NASH [4] but improve AIH-related 
necroinflammation [5]. Third, the natural course and postintervention prognosis remain 
to be characterized. To our knowledge, 8 cases of biopsy-proven NAFLD-AIH overlap 
syndrome have been reported to date [2, 3, 6], 3 with NASH and 5 with NAFLD (the 
latter without detailed information on the presence of steatohepatitis). Among these, 
2 cases of NASH-AIH overlap were treated with corticosteroid, but histological changes 
as revealed by follow-up liver biopsies have not yet been reported [6]. 
In this report we describe a patient with NASH-AIH overlap who successfully achieved 
histological remission of AIH as well as resolution of NASH with a combination of 
prednisolone therapy and weight loss. This is the first report demonstrating that 
corticosteroids improve the prognosis of NASH-AIH overlap.  
Case Report 
A 57-year-old female patient was referred to our hospital with a 2-year history of low-grade but 
gradually progressing aminotransferase elevation. On admission, clinical examination was normal 
but blood tests revealed elevated liver enzymes, i.e., AST 174 IU/l (normal <37 IU/l), ALT 302 IU/l 
(normal <39 IU/l), ALP 263 IU/l (normal <359 IU/l), and γ-GTP 120 IU/l (normal <75 IU/l). Her 
serum autoantibody profile was as follows: anti-nuclear antibody 1,280× (speckled), anti-smooth 
muscle antibody 80×, and anti-SS-A 64×, but anti-mitochondria antibody was negative. Serum IgG 
was increased to 2,370 mg/dl (normal <1,700 mg/dl) and human leukocyte antigen was found to be 
DR3
–/DR4
+. Viral markers for HBV and HCV were both negative. Elevated fasting blood glucose 
(123 mg/dl) coupled with increased HbA1c (7.3%) indicated comorbid diabetes mellitus. The 
homeostasis model assessment of insulin resistance (HOMA-R) was 11.4, though the patient was not 
significantly obese (body mass index was 23.6). She had no history of regular alcohol consumptions. 
As abdominal CT scan and ultrasonography both suggested the presence of fatty liver, subsequent liver 
biopsy was required to narrow down the differential diagnosis that included NAFLD, AIH, and their 
concurrence. Liver histology (fig. 1) revealed severe interface hepatitis with mononuclear cells infiltrates 
including plasma cells. Steatosis and pericellular/bridging fibrosis were also prominent, accompanied by 
hepatocyte ballooning, implicating concurrence with the histological features of steatohepatitis.  
A diagnosis of NASH-AIH overlap was made (AIH score was 18, i.e., definite, together with NASH 
grade 2/stage 3 according to the Blunt classification system), and 30 mg of prednisolone per day p.o. was 
initiated. Prednisolone exacerbated the patient’s diabetes during the 1st week of treatment, necessitating 
the administration of rapid-acting insulin. As aminotransferase levels began to decrease shortly after the Case Rep Gastroenterol 2011;5:553–557 
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initiation of treatment, prednisolone was gradually tapered to 15 mg/day over 6 months until liver 
enzymes normalized. The patient also lost 6 kg during this period. Prednisolone was further tapered to 
5 mg/day over the next 12 months, without any hepatitis flare-up. Ursodeoxycholic acid 600 mg/day 
p.o. was then added to prednisolone as maintenance therapy, and rapid-acting insulin was subsequently 
replaced with an oral hypoglycemic agent. Follow-up liver tissue examination performed 40 months 
after diagnosis revealed only minimal inflammatory infiltrates in the portal area without any histological 
evidence of steatohepatitis (fig. 2). The fibrosis score established by Ishak et al. [7] decreased from 4 at 
diagnosis to 1, while the NAFLD activity score [8] (scale developed by the NASH Clinical Research 
Network) decreased from 6 to 2. 
Discussion 
In this report we present a NASH-AIH overlap patient who successfully achieved 
histological remission of both AIH and NASH following prednisolone therapy. To our 
knowledge, this report is the first to document the detailed clinical course of NASH-AIH 
overlap during prednisolone therapy, accompanied by documentation of histological 
improvement. 
Information regarding treatment regimen was presented in 6 out of 8 NAFLD-AIH 
overlap cases in the literature [2, 3, 6]: 2 patients were given prednisolone combined with 
diet therapy, resulting in a partial biochemical response [6]. On the other hand, 1 out of 
2 patients treated with ursodeoxycholic acid and modified diet was reported to show 
normalized aminotransferases [3]. The remaining 2 cases were not treated, in 1 case due 
to coexisting diabetes and dyslipidemia despite the presence of definite AIH [2]. Due to 
the anti-inflammatory action of glucocorticoid, fibrosis in AIH commonly improves or 
does not progress during therapy [9–11]. Reflecting glucocorticoids’ cell- and 
tissue-specific mode of action through the glucocorticoid receptor, these compounds are 
also steatogenic in both clinical and experimental settings [12]. Persistently elevated 
glucocorticoid levels have been associated with fatty liver development and their 
consequent phenotype in NAFLD [13]. Moreover, dose-dependent association of 
glucocorticoid with secondary NASH was demonstrated in patients with systemic lupus 
erythematosus [14], and hepatic fat accumulation has been documented in patients with 
Cushing’s syndrome. In accordance with clinical findings, Lemke et al. [15] recently 
reported that liver-specific glucocorticoid receptor knock-down by shRNA, through 
induction of transcriptional repressor hairy enhancer of split 1 (Hes1), caused a 
pronounced decrease in hepatic triglyceride levels in the livers of obese db/db mice.  
The above findings raise concerns about the use of glucocorticoids in the treatment 
of NAFLD-AIH overlap. In our case the clinical benefit of prednisolone’s 
immunosuppressive and fibrolytic action clearly outweighed its steatogenic properties. 
Our findings thus emphasize the need of appropriate immunosuppressive treatment 
even in comorbid AIH and NASH, though interindividual differences and genetic 
susceptibility may affect the glucocorticoids’ steatogenic actions. It should be noted that 
our study used a shorter duration and lower total dosage of prednisolone administration 
for AIH compared to that for systemic lupus erythematosus, and this may not exacerbate 
concurrent NASH if it is accompanied with appropriate diet therapy, the gold standard 
treatment for NASH. 
Loria et al. [6] reported that 3 out of 84 NAFLD patients (3.6%) were diagnosed with 
true NASH-AIH overlap after liver biopsy, whereas 1 out of 212 Japanese NAFLD Case Rep Gastroenterol 2011;5:553–557 
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patients (0.5%) had definite AIH [3]. Given ethnic differences in susceptibility to the 
development of NASH-AIH overlap, the increasing prevalence of NAFLD worldwide 
probably makes NASH-AIH overlap more clinically relevant. Obviously, the false 
diagnosis of overlapped AIH in female NASH patients who have not undergone liver 
biopsy should be avoided, but true diagnosis of NASH-AIH accompanied by appropriate 
corticosteroid induction is needed to prevent disease progression. 
We presented a patient with NASH-AIH overlap who achieved histological remission 
as a result of prednisolone therapy. Future prospective studies and the accumulation of 
definite cases are needed to validate the effectiveness of corticosteroid therapy for 
NASH-AIH overlap. 
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Fig. 1. Liver histology before therapy. a Azan stain (10×). Steatosis and pericellular/bridging fibrosis 
were prominent. Over 33% of the surface area was affected by steatosis of grade 2/stage 3 by the Blunt 
classification. b H&E stain (100×). Severe interface hepatitis with mononuclear cell infiltrates including 
plasma cells was revealed in the portal area. c H&E stain (100×). Hepatocyte ballooning, Mallory bodies, 
and infiltration of neutrophils to hepatic parenchyma are apparent around the central vein. The NAFLD 
activity score was calculated to be 6. 
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Fig. 2. Follow-up liver histology 40 months after diagnosis. a Azan stain (10×). Pericellular/bridging 
fibrosis was decreased. b H&E stain (100×). Interface hepatitis was improved, and only minimal 
inflammatory infiltrates are disclosed in the portal area. c H&E stain (40×). The NAFLD activity score 
had improved from 6 to 2, with no histological evidence of steatohepatitis around the central vein. 
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